{"id":"W3128747576","doi":"10.1016/s0140-6736(21)00125-2","title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":297,"is_retracted":false,"has_abstract":false,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"UCB Pharma","keywords":"Medicine; Ustekinumab; Psoriasis; Placebo; Psoriasis Area and Severity Index; Clinical endpoint; Internal medicine; Adverse effect; Clinical trial; Randomization; Dosing; Body surface area; Plaque psoriasis; Randomized controlled trial; Dermatology; Adalimumab; Disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001778655,0.0003095276,0.00109651,0.00003859911,0.0003907067,0.00004511468,0.0001750317,0.0001699257,0.000127847],"category_scores_gemma":[0.0000772909,0.0001732598,0.0001589092,0.0001061808,0.0001223549,0.00005327611,0.00005353759,0.00009706619,0.00002505721],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007261091,"about_ca_system_score_gemma":0.0001022411,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001667871,"about_ca_topic_score_gemma":0.0004556089,"domain_scores_codex":[0.9984499,0.0003991558,0.0003431757,0.0004009946,0.00005422007,0.0003525837],"domain_scores_gemma":[0.9953381,0.003850193,0.0001865017,0.0004911805,0.00008810027,0.00004588733],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9660681,0.001191637,0.00001486875,0.000007722562,0.004339782,0.00000581468,0.003898362,0.00007038213,0.004123049,0.000136939,0.0009362344,0.01920713],"study_design_scores_gemma":[0.9328876,0.002368209,0.0002106139,0.00002331377,0.001998944,0.000009963113,0.001080306,0.0001812503,0.04190538,0.00002627638,0.01910516,0.0002030477],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860102,0.004501835,0.00008766007,0.001729654,0.001001575,0.003849022,0.002641629,0.00003248239,0.0001459197],"genre_scores_gemma":[0.9963093,0.001553975,0.0001703493,0.000112262,0.0004144442,0.0006441635,0.0003690378,0.00002179126,0.0004047184],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03778233,"threshold_uncertainty_score":0.7065328,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09074387936814433,"score_gpt":0.3299520541258157,"score_spread":0.2392081747576714,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}